Shijiazhuang Recovery Star Medical Device Co., Ltd. appears in FDA public records as the applicant on a single 510(k) premarket notification, K262285, for a UV Phototherapy Device. The submission was received July 6, 2026, and decided October 5, 2026, with a substantially equivalent decision under product code FTC and regulation 878.4630, Light, Ultraviolet, Dermatological. The device is listed in device class 2, reviewed by the General, Plastic Surgery panel, as a Traditional submission with a summary statement. The record identifies five model designations in the device name. [1][4][8]

The documented product and its model designations

The cleared device is named UV Phototherapy Device, with five parenthetical model designations: KZX-308nm-BL65, KZX-308nm-BL55, KZX-308nm-BL50, KZX-308nm-BL45 and KZX-308nm-BL35. FDA classifies it under product code FTC, regulation number 878.4630, with the classification name Light, Ultraviolet, Dermatological, in class 2. The advisory committee and review panel are recorded as General, Plastic Surgery. The submission is recorded as Traditional clearance, not third-party reviewed, with a summary statement. [1][4][8]

A 510(k) summary excerpt indexed for this record describes the device as intended for the treatment of psoriasis, vitiligo, seborrheic dermatitis, atopic dermatitis and leukoderma, used on intact skin only. The same excerpt states that no reference devices were used in the submission. That summary text is the only description of intended use in the public documents; no component list, wavelength specification or performance data is documented beyond the model names. [8]

Filing timeline and review record

FDA received K262285 on July 6, 2026, and issued a substantially equivalent decision on October 5, 2026. One third-party index calculates the interval as 91 days. The decision code is SESE, described as Substantially Equivalent. The applicant of record is Shijiazhuang Recovery Star Medical Device Co., Ltd., with a contact named as Adrian Tse. [1][4][6]

The clearance also appears in FDA's published list of 510(k) final decisions rendered since October 1, 2026, where K262285 is listed with a Substantially Equivalent decision and the applicant name Shijiazhuang. The same record appears in an FDA premarket notification listing file dated November 9, 2026, carrying the July 6 receipt date, the October 5 decision date, product code FTC and Traditional submission type. [3][5]

Applicant identity and address of record

The FDA record gives the applicant address as A8-2-4, Kelin Industrial Park, # 8 Yuanhang Rd., Sijiazhuang, Shijiazhuang, postal code 050200, country code CN. This is a filing address, not a verified headquarters. The record lists a contact name, Adrian Tse, and no parent company, brand owner or corporate affiliate is identified in the public documents. [1][5][6]

One company-indexing tool states that, as of November 19, 2026, FDA public records list the firm with one 510(k) clearance, the October 5, 2026 clearance for the UV Phototherapy Device. That count reflects the records the tool indexed at that date and is not a statement of total company output, sales or portfolio breadth. [7]

Related records and what is not documented

A third-party index lists other product code FTC clearances from different applicants, including K262885 for a 308nm Ultraviolet Light Therapy Device by Guangxi Hope Medical Devices Technology Co., Ltd., decided October 14, 2026, and earlier Daavlin phototherapy clearances. These are separate applicants' records and are not attributed to Shijiazhuang Recovery Star. [4]

The same index reports no predicate lineage recorded for K262285, no UDI data, no FDA recalls, no MAUDE adverse events and no appearance on FDA device lists. Those absences describe what that index held at the time of retrieval; they are not evidence of safety performance. No website, ownership structure, certifications, customers or commercial availability are documented in the public documents. [6]